Cardiovascular endocrinology: Introduction

Endocrine Reviews

Volumn 24, Issue 3, 2003, Pages 253-260

  Baxter, John D ^a,c   Young Jr , William F ^b   Webb, Paul ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; LIVER RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR; SCAVENGER RECEPTOR; UNCLASSIFIED DRUG;

ACROMEGALY; CALCIUM BLOOD LEVEL; CALCIUM TRANSPORT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PERFORMANCE; CARDIOVASCULAR SYSTEM; CHOLESTEROL SYNTHESIS; CORONARY RISK; CUSHING DISEASE; DYSLIPIDEMIA; EDITORIAL; ENDOCRINE SYSTEM; HEART PROTECTION; HORMONE SUBSTITUTION; HYPERTENSION; INSULIN RESISTANCE; LIPID STORAGE; LIPOPROTEIN SYNTHESIS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; STEROIDOGENESIS; THYROID DISEASE;

EID: 0038646356     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2003-0099     Document Type: Editorial

References (55)

1. Ribeiro RCJ, Kushner PJ, Baxter JD 1995 The nuclear hormone receptor gene superfamily. Annu Rev Med 46:443-453
2. Glass CK, Rosenfeld MG 2000 The coregulator exchange in transcriptional functions of nuclear receptors. Genes Dev 14:121-141
3. McKenna NJ, O'Malley BW 2000 From ligand to response: generating diversity in nuclear receptor coregulator function. J Steroid Biochem Mol Biol 74:351-356
4. Libby P 2002 Inflammation in atherosclerosis. Nature 420:868-874
5. Chawla A, Repa JJ, Evans RM, Mangelsdorf DJ 2001 Nuclear receptors and lipid physiology: opening the X-files. Science 294:1866-1870
6. Bocher V, Pineda-Torra I, Fruchart JC, Staels B 2002 PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann NY Acad Sci 967:7-18
7. Hihi AK, Michalik L, Wahli W 2002 PPARs: transcriptional effectors of fatty acids and their derivatives. Cell Mol Life Sci 59:790-798
8. Lehman JJ, Kelly DP 2002 Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail Rev 7:175-185
9. Rieusset J, Touri F, Michalik L, Escher P, Desvergne B, Niesor E, Wahli W 2002 A new selective peroxisome proliferator-activated receptor gamma antagonist with antiobesity and antidiabetic activity. Mol Endocrinol 16:2628-2644
10. Edwards PA, Kast HR, Anisfeld AM 2002 BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. J Lipid Res 43:2-12
11. Laffitte BA, Tontonoz P 2002 Orphan nuclear receptors find a home in the arterial wall. Curr Atheroscler Rep 4:213-221
12. Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P 2003 Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med 9:213-219
13. Stier Jr CT, Chander PN, Rocha R 2002 Aldosterone as a mediator in cardiovascular injury. Cardiol Rev 10:97-107
14. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P 2002 Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension 40:892-896
15. Rossi E, Regolisti G, Negro A, Sani C, Davoli S, Perazzoli F 2002 High prevalence of primary aldosteronism using postcaptopril plasma aldosterone to renin ratio as a screening test among Italian hypertensives. Am J Hypertens 15:896-902
16. Young Jr WF 1999 Primary aldosteronism: a common and curable form of hypertension. Cardiol Rev 7:207-214
17. Golub MS 2001 The adrenal and the metabolic syndrome. Curr Hypertens Rep 3:117-120
18. Baxter JD 2000 Advances in glucocorticoid therapy. Adv Intern Med 45:317-349
19. Mendelsohn ME 2002 Protective effects of estrogen on the cardiovascular system. Am J Cardiol 89:12E-17E; discussion 17E-18E
20. Kuller LH 2003 Hormone replacement therapy and risk of cardiovascular disease: implications of the results of the Women's Health Initiative. Arterioscler Thromb Vasc Biol 23:11-16
21. Baxter JD, Dillmann WH, West BL, Huber R, Furlow JD, Fletterick RJ, Webb P, Apriletti JW, Scanlan TS 2001 Selective modulation of thyroid hormone receptor action. J Steroid Biochem Mol Biol 76:31-42
22. Klein I, Ojamaa K 2001 Thyroid hormone and the cardiovascular system. N Engl J Med 344:501-509
23. Duntas LH 2002 Thyroid disease and lipids. Thyroid 12:287-293
24. Morkin E, Pennock GD, Spooner PH, Bahl JJ, Goldman S 2002 Clinical and experimental studies on the use of 3,5-diiodothyropropionic acid, a thyroid hormone analogue, in heart failure. Thyroid 12:527-533
25. Miano JM, Berk BC 2001 Retinoids: new insight into smooth muscle cell growth inhibition. Arterioscler Thromb Vasc Biol 21:724-726
26. Chien KR, Olson EN 2002 Converging pathways and principles in heart development and disease: CV@CSH. Cell 110:153-162
27. Jetten AM, Kurebayashi S, Ueda E 2001 The ROR nuclear orphan receptor subfamily: critical regulators of multiple biological processes. Prog Nucleic Acid Res Mol Biol 69:205-247
28. Virdis A, Schiffrin EL 2003 Vascular inflammation: a role in vascular disease in hypertension? Curr Opin Nephrol Hypertens 12:181-187
29. Pearce D 2001 The role of SGK1 in hormone-regulated sodium transport. Trends Endocrinol Metab 12:341-347
30. Bernstein D 2002 Cardiovascular and metabolic alterations in mice lacking β1- and β2-adrenergic receptors. Trends Cardiovasc Med 12:287-294
31. Jose PA, Eisner GM, Felder RA 2000 Renal dopamine and sodium homeostasis. Curr Hypertens Rep 2:174-183
32. Manger WM, Gifford RW 2002 Pheochromocytoma. J Clin Hypertens (Greenwich) 4:62-72
33. Siragy HM, Carey RM 2001 Angiotensin type 2 receptors: potential importance in the regulation of blood pressure. Curr Opin Nephrol Hypertens 10:99-103
34. McFarlane SI, Sowers JR 2003 Cardiovascular endocrinology 1: aldosterone function in diabetes mellitus: effects on cardiovascular and renal disease J Clin Endocrinol Metab 88:516-523
35. Patterson JH 2003 Angiotensin II receptor blockers in heart failure. Pharmacotherapy 23:173-182
36. Mauer M, Zinman B, Gardiner R, Drummond KN, Suissa S, Donnelly SM, Strand TD, Kramer MS, Klein R, Sinaiko AR 2002 ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 3:262-269
37. Izzo JL, Moser M 2002 Clinical impact of renin-angiotensin system blockade: angiotensin-converting enzyme inhibitors vs. angiotensin receptor antagonists. J Clin Hypertens (Greenwich) 4(Suppl 2):11-19
38. Tavi P, Laine M, Weckstrom M, Ruskoaho H 2001 Cardiac mechanotransduction: from sensing to disease and treatment. Trends Pharmacol Sci 22:254-260
39. Krebs LJ, Arnold A 2002 Molecular basis of hyperparathyroidism and potential targets for drug development. Curr Drug Targets Immune Endocr Metabol Disord 2:167-179
40. Stenstrom G, Svardsudd K 1986 Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220:225-232
41. Beard CM, Sheps SG, Kurland LT, Carney JA, Lie JT 1983 Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58:802-804
42. Rihal CS, Textor SC, Breen JF, McKusick MA, Grill DE, Hallett JW, Holmes Jr DR 2002 Incidental renal artery stenosis among a prospective cohort of hypertensive patients undergoing coronary angiography. Mayo Clin Proc 77:309-316
43. Textor SC 2000 Epidemiology and clinical presentation. Semin Nephrol 20:426-431
44. Reaven G 2002 Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106:286-288
45. Pi-Sunyer X 2003 A clinical view of the obesity problem. Science 299:859-860
46. Brown BG, Zhao XQ, Sacco DE, Albers JJ 1993 Atherosclerosis regression, plaque disruption, and cardiovascular events: a rationale for lipid lowering in coronary artery disease. Annu Rev Med 44:365-376
47. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC, Havel RJ 1990 Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264:3007-3012
48. Austin MA, Hokanson JE, Edwards KL 1998 Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 81:7B-12B
49. Libby P, Aikawa M 2003 Mechanisms of plaque stabilization with statins. Am J Cardiol 91(Suppl 4A):4-8
50. Biondi B, Palmieri EA, Lombardi G, Fazio S 2002 Effects of subclinical thyroid dysfunction on the heart. Ann Intern Med 137:904-914
51. Sawin CT 2002 Subclinical hyperthyroidism and atrial fibrillation. Thyroid 12:501-503
52. Canaris GJ, Manowitz NR, Mayor G, Ridgway EC 2000 The Colorado thyroid disease prevalence study. Arch Intern Med 160:526-534
53. Meier C, Staub JJ, Roth CB, Guglielmetti M, Kunz M, Miserez AR, Drewe J, Huber P, Herzog R, Muller B 2001 TSH-controlled L-thyroxine therapy reduces cholesterol levels and clinical symptoms in subclinical hypothyroidism: a double blind, placebo-controlled trial (Basel Thyroid Study). J Clin Endocrinol Metab 86:4860-4866
54. Findling JW, Raff H 2001 Diagnosis and differential diagnosis of Cushing's syndrome. Endocrinol Metab Clin North Am 30:729-747
55. Whitworth JA, Schyvens CG, Zhang Y, Andrews MC, Mangos GJ, Kelly JJ 2002 The nitric oxide system in glucocorticoid-induced hypertension. J Hypertens 20:1035-1043